Experts question data showing that an experimental therapy that parents deliver to babies with early signs of autism can lessen the intensity of the children’s traits and lower their chances of diagnosis at age 3.

The stubborn lack of treatments for fragile X syndrome — a leading cause of inherited intellectual disability and autism — is spurring researchers to revise clinical trial techniques and revisit old drug candidates.

Hundreds of preschool-aged children in Kentucky began taking antipsychotic medicines in 2012, according to an analysis of Medicaid records. Lohr discusses what it will it take to get them behavioral therapies instead.

Some types of restricted and repetitive behaviors become more prevalent among autistic children and teenagers over time, depending on their age and intellectual ability, whereas others decrease.

For 40 years, the preponderance of autism research has focused on understanding the causes and characteristics of the condition rather than testing assessments or interventions in community settings.

On 28 September, Jeremy Veenstra-VanderWeele, professor of psychiatry at Columbia University, spoke about goals for developing new drugs for autism — and the barriers researchers may encounter.

The finding that MDMA and an experimental serotonin agonist increase sociability across six different model mice suggests that disparate autism-linked mutations converge on the same underlying pathways.

Disparities in state services for autism are driving families to relocate. But not everyone can afford to move, and others find that their new home also has faults.

Neurons in mice with an autism-linked mutation sprout extraneous protrusions, an overgrowth accompanied by above-average motor learning. Inhibiting a cell signaling pathway reverses the effect.

Roughly 30 percent of people with autism plus another condition, such as anxiety, are prescribed three or more psychotropic medicines. And that mix frequently changes from year to year.